Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease
Date:3/2/2010

call on Wednesday, March 3, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 877-303-2523 for domestic callers and 1-253-237-1755 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer
'/>"/>

SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
5. Medivation Announces Pricing of Public Offering
6. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
7. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
8. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
9. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
10. Medivation Presents New Data on Dimebons Novel Mechanism of Action
11. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Pa., Dec. 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... announced,that the company will attend the 20th Annual Piper ... The 20th Annual Piper Jaffray Health Care Conference ... December 3, 2008, at the New York,Palace Hotel in ...
... Tigermed Consulting Co., Ltd,a leading Contract Research ... has,established a subsidiary, Hunan Tigermed Xiangya Drug ... (CSU). The establishment of Tigermed Xiangya ... nationwide first-rate Phase,I Clinical Laboratory, and further ...
... COPENHAGEN, December 1 A strong pipeline makes the,Copenhagen Region ... candidates in preclinical and clinical development, Denmark,ranks third in Europe. ... Also in term of ... largest pipeline growth among the countries in Europe. , ...
Cached Biology Technology:Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya) 2Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe 2
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Even bird brains can get to know an entire continent ... do so, suggests a Princeton research team. The ... way to their winter nesting grounds even after being thrown ... to compensate for the displacement. However, similarly displaced juvenile birds, ...
... today its involvement in an expanded access program ... for phenylketonuria (PKU), a rare genetic metabolic disorder ... can result in severe mental retardation. Currently, there ... program at Nationwide Childrens. Under an expanded ...
... at the Wildlife Conservation Society and other institutions declare ... in South Asia could double the number of tigers ... The study appears in the most recent edition ... examined 157 reserves throughout the Indian subcontinentcomprising India, Bangladesh, ...
Cached Biology News:For migrating sparrows, kids have a compass, but adults have the map 2Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... Heat activated ,• Eliminates nonspecific products ... Excellent specificity allows extension through DNA ... ,• Leaves an 'A' overhang ... of GeneChoice DNA Polymerase that remains ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: